drugset / Trial / NCT02631096
Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy
RandomizedParallel-groupSingle-blindTreatment
Summary
The study is a phase 2a, single blind, randomized, placebo controlled, study evaluating the safety, anti-viral activity, and pharmacokinetics (PK) following multiple doses of intravenous ARB-001467
Timeline
- Start
- 2015-12
- Primary completion
- 2018-05-18
- Completion
- 2018-05-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARB-001467 | Unknown | 0.2 mg/kg | Intravenous |
| Subject | ARB-001467 | Unknown | 0.4 mg/kg | Intravenous |